Wednesday, 26 August 2026European Markets

DGB GROUP N.V. Stock Is 27% Down In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of DGB GROUP N.V. (AEX-Index: DGB.AS) fell by a staggering 27.32% in 21 sessions from €0.8 to €0.58 at 05:08 EST on Monday, following the last session's upward trend. AEX-Index is jumping 0.25% to €752.99, after two consecutive sessions in a row of gains.

DGB GROUP N.V.'s last close was €0.58, 51.67% under its 52-week high of €1.20.

About DGB GROUP N.V.

DGB Group N.V. invests in, develops, and manages biodiversity and carbon offset projects for businesses and governments in the Netherlands and internationally. The company provides nature-based solutions, as well as focuses on nature conservation activities. It is also involved in the trees breeding and planting business. The company was formerly known as Verenigde Nederlandse Compagnie N.V. and changed its name to DGB Group N.V. in January 2018. DGB Group N.V. was founded in 1957 is based in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, DGB GROUP N.V. has a trailing twelve months EPS of €-0.12.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -19%.

More news about DGB GROUP N.V. (DGB.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com